Spoken Alpha
Marker Therapeutics, Inc.
Marker Therapeutics develops non-genetically engineered T cell immunotherapies for treating blood cancers and solid tumors.
Marker Therapeutics, Inc is a Healthcare company operating in Biotechnology with a $19.3M market cap.
MRKR beat consensus EPS by 0.6% in Q2 FY2026, reported Aug 13, 2026.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for MRKR.
$ curl https://api.spokenalpha.com/v1/companies/MRKRFAQ
Spoken Alpha indexes MRKR's earnings call transcripts at https://spokenalpha.com/companies/MRKR. Each call links to attributed speakers and parsed analyst Q&A. Marker Therapeutics, Inc.'s own investor relations page is at https://ir.markertherapeutics.com/.
Marker Therapeutics, Inc. (MRKR) held its most recent earnings call on 2021-05-12, covering fiscal Q1 2021.
Marker Therapeutics, Inc. (MRKR) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-13 | $-0.09 | $-0.25 | +64.0% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-14 | $-0.16 | $-0.19 | +15.8% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-18 | $-0.04 | $-0.19 | +79.0% | $1.1M | — | — | EODHD |
| Q3 FY2025 | 2025-11-12 | $-0.12 | $-0.21 | +42.9% | $1.2M | — | — | EODHD |
| Q2 FY2025 | 2025-08-13 | $-0.29 | $-0.27 | -7.4% | $861.2K | — | — | EODHD |
| Q1 FY2025 | 2025-05-14 | $-0.40 | $-0.66 | +39.4% | $349.1K | — | — | EODHD |
| Q4 FY2024 | 2025-03-23 | $-0.42 | $-0.22 | -90.9% | $2.3M | — | — | EODHD |
| Q3 FY2024 | 2024-11-13 | $-0.26 | $-0.39 | +33.3% | $1.9M | — | — | EODHD |
| Q2 FY2024 | 2024-08-13 | $-0.25 | $-0.43 | +41.9% | $1.2M | — | — | EODHD |
| Q1 FY2024 | 2024-05-14 | $-0.27 | $-0.25 | -8.0% | $1.2M | — | — | EODHD |
| Q4 FY2023 | 2024-03-25 | $-0.48 | $-1.00 | +52.0% | $1.1M | — | — | EODHD |
| Q3 FY2023 | 2023-11-08 | $-0.34 | — | — | $257.6K | — | — | EODHD |
| Q2 FY2023 | 2023-08-13 | $0.29 | — | — | $762.7K | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-0.57 | $-0.80 | +28.8% | $1.2M | — | — | EODHD |
| Q4 FY2022 | 2023-03-21 | $-3.27 | $-1.00 | -100.0% | $759.1K | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $-0.80 | $-1.30 | +38.5% | $999.6K | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $-1.10 | $-1.03 | -6.8% | $790.5K | — | — | EODHD |
| Q1 FY2022 | 2022-05-12 | $-1.20 | $-1.33 | +9.8% | $964.3K | — | — | EODHD |
| Q4 FY2021 | 2022-03-16 | $-1.10 | $-1.27 | +13.4% | $1.2M | — | — | EODHD |
| Q3 FY2021 | 2021-11-08 | $-1.50 | $-1.27 | -18.1% | $0 | — | — | EODHD |
Source: EODHD. MRKR reported actuals as published; sparse fields render as —.